{"id":174097,"date":"2026-01-22T12:08:31","date_gmt":"2026-01-22T17:08:31","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=174097"},"modified":"2026-01-22T12:08:31","modified_gmt":"2026-01-22T17:08:31","slug":"alivus-life-sciences-shares-climb-as-third-quarter-profit-rises-9-7","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/alivus-life-sciences-shares-climb-as-third-quarter-profit-rises-9-7\/","title":{"rendered":"Alivus Life Sciences shares climb as third-quarter profit rises 9.7%"},"content":{"rendered":"\n<p>Alivus Life Sciences Ltd (NSE: ALIVUS) shares increased by 1.36% to \u20b9873.00 on the National Stock Exchange on Thursday. The stock reached an intraday high of \u20b9889.95 and a low of \u20b9819.00 following the announcement of its financial results for the third quarter of fiscal year 2026. The company\u2019s market capitalization stood at \u20b9107.10 billion as of Thursday&#8217;s close, which is approximately $1.17 billion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Latest Quarterly Results<\/strong><\/h2>\n\n\n\n<p>Alivus Life Sciences reported a consolidated revenue from operations of \u20b96.73 billion for the quarter ended December 31, 2025. This represents a 4.8% increase compared to \u20b96.42 billion in the same period of the previous fiscal year. Consolidated net profit reached \u20b91.50 billion, a year-on-year growth of 9.71% from \u20b91.37 billion.<\/p>\n\n\n\n<p>Operating profit, measured as EBITDA, rose to \u20b92.31 billion, with margins expanding to a record 34.37% from 31.3% in the year-ago quarter.<\/p>\n\n\n\n<p><strong><em>Segment performance highlights:<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Generic API:<\/strong> Revenue from the active pharmaceutical ingredient (API) segment contributed 89% of total income.<\/li>\n\n\n\n<li><strong>CDMO:<\/strong> The contract development and manufacturing organization (CDMO) segment recorded volume growth, although the company noted continued focus on high-potency molecules.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Financial Trends<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1000\" height=\"600\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Code_Generated_Image-3.png\" alt=\"\" class=\"wp-image-174729\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Code_Generated_Image-3.png 1000w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Code_Generated_Image-3-300x180.png 300w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Code_Generated_Image-3-768x461.png 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1000\" height=\"600\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Code_Generated_Image-2.png\" alt=\"\" class=\"wp-image-174724\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Code_Generated_Image-2.png 1000w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Code_Generated_Image-2-300x180.png 300w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Code_Generated_Image-2-768x461.png 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Full-Year Results Context<\/strong><\/h2>\n\n\n\n<p>For the full fiscal year ended March 31, 2025, the company (formerly Glenmark Life Sciences) reported a total revenue of \u20b923.87 billion. Annual profit stood at \u20b94.86 billion. Directional trends over the last two fiscal cycles show a stable expansion in revenue and a consistent maintenance of debt-free status.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Business &amp; Operations Update<\/strong><\/h2>\n\n\n\n<p>The company transitioned to its new corporate identity, Alivus Life Sciences, following the acquisition of a majority stake by Nirma Limited. During the quarter, the company reported the addition of new technology platforms, including flow chemistry, and the advancement of its high-potent API pipeline, which currently includes 21 molecules. Capacity expansion at the Solapur greenfield site and brownfield additions at Dahej and Ankleshwar remain in progress to support long-term volume requirements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>M&amp;A or Strategic Moves<\/strong><\/h2>\n\n\n\n<p>Nirma Limited remains the majority promoter following its 75% stake acquisition from Glenmark Pharmaceuticals. No new institutional-level mergers or acquisitions were announced during the third quarter disclosure.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Equity Analyst Commentary<\/strong><\/h2>\n\n\n\n<p>Institutional research from Kotak Institutional Equities and Marketsmojo noted the company&#8217;s margin expansion as a result of a favorable product mix and lower raw material input costs. Analysts indicated that the CDMO segment&#8217;s recovery and the scaling of the oncology and iron complex portfolios are key monitoring factors for the next fiscal year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Guidance &amp; Outlook<\/strong><\/h2>\n\n\n\n<p>Alivus Life Sciences has indicated a volume growth target in the mid-teens for the remainder of the fiscal year. The company identified the commercialization of new molecules and the stabilization of logistics costs as primary factors to watch for in the upcoming quarter.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Performance Summary<\/strong><\/h2>\n\n\n\n<p>Alivus Life Sciences stock closed 1.36% higher at \u20b9873.00. The company achieved a record quarterly revenue of \u20b96.73 billion and a net profit of \u20b91.50 billion. Record EBITDA margins of 34.37% reflected operational efficiency gains within the core Generic API segment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alivus Life Sciences Ltd (NSE: ALIVUS) shares increased by 1.36% to \u20b9873.00 on the National Stock Exchange on Thursday. The stock reached an intraday high of \u20b9889.95 and a low of \u20b9819.00 following the announcement of its financial results for the third quarter of fiscal year 2026. The company\u2019s market capitalization stood at \u20b9107.10 billion [&hellip;]<\/p>\n","protected":false},"author":2398,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[10162],"class_list":["post-174097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-healthcare-stocks","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":168660,"url":"https:\/\/alphastreet.com\/india\/alivus-life-sciences-ltd-q4fy25-12-rise-in-revenue\/","url_meta":{"origin":174097,"position":0},"title":"Alivus Life Sciences Ltd Q4FY25; 12% rise in Revenue","author":"Divyansh_Kasana","date":"June 5, 2025","format":false,"excerpt":"Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/L-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":173671,"url":"https:\/\/alphastreet.com\/india\/alivus-life-sciences-lt-alivus-q3-2025-earnings-call-transcript\/","url_meta":{"origin":174097,"position":1},"title":"Alivus Life Sciences Lt (ALIVUS) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Alivus Life Sciences Lt (NSE: ALIVUS) Q3 2025 Earnings Call dated Jan. 23, 2025 Corporate Participants: Unidentified Speaker Yasir Rawjee \u2014 Managing Director and Chief Executive Officer Tushar Mistry \u2014 Chief Financial Officer Analysts: Ahmed Madha \u2014 Analyst Sajal Kapoor \u2014 Analyst Harsh Shah \u2014 Analyst Karthik Swaminathan \u2014 Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":178974,"url":"https:\/\/alphastreet.com\/india\/brigade-enterprises-shares-close-flat-following-q3-results\/","url_meta":{"origin":174097,"position":2},"title":"Brigade Enterprises Shares Close Flat Following Q3 Results","author":"Staff Correspondent","date":"February 2, 2026","format":false,"excerpt":"Brigade Enterprises Limited (NSE: BRIGADE) shares closed at INR 738.40 on February 2, 2026, recording a 0.14% intraday decline on the National Stock Exchange. The stock reached a session high of INR 745.40 and a session low of INR 727.00. The company's market capitalization stands at INR 180.60 billion. Latest\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173669,"url":"https:\/\/alphastreet.com\/india\/alivus-life-sciences-lt-alivus-q1-2026-earnings-call-transcript\/","url_meta":{"origin":174097,"position":3},"title":"Alivus Life Sciences Lt (ALIVUS) Q1 2026 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Alivus Life Sciences Lt (NSE: ALIVUS) Q1 2026 Earnings Call dated Aug. 02, 2025 Corporate Participants: Unidentified Speaker Soumi Rao Yasir Rawjee \u2014 Managing Director and Chief Executive Officer Tushar Mistry \u2014 Chief Financial Officer Analysts: Unidentified Participant Ahmed Madha \u2014 Analyst Tarang Agarwal \u2014 Analyst murali krishna \u2014 Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177405,"url":"https:\/\/alphastreet.com\/india\/alivus-life-sciences-lt-alivus-q3-2026-earnings-call-transcript\/","url_meta":{"origin":174097,"position":4},"title":"Alivus Life Sciences Lt (ALIVUS) Q3 2026 Earnings Call Transcript","author":"News desk","date":"January 23, 2026","format":false,"excerpt":"Alivus Life Sciences Lt (NSE: ALIVUS) Q3 2026 Earnings Call dated Jan. 22, 2026 Corporate Participants: Soumi Rao \u2014 General Manager, Corporate Communications and CSR Yasir Rawjee \u2014 Managing Director and Chief Executive Officer Tushar Mistry \u2014 Chief Financial Officer Analysts: Unidentified Participant Presentation: operator It. It. Ladies and gentlemen,\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173670,"url":"https:\/\/alphastreet.com\/india\/alivus-life-sciences-lt-alivus-q4-2025-earnings-call-transcript\/","url_meta":{"origin":174097,"position":5},"title":"Alivus Life Sciences Lt (ALIVUS) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Alivus Life Sciences Lt (NSE: ALIVUS) Q4 2025 Earnings Call dated May. 16, 2025 Corporate Participants: Soumi Rao \u2014 Investor Relations Yasir Rawjee \u2014 Managing Director and Chief Executive Officer Tushar Mistry \u2014 Chief Financial Officer & Senior Vice President Analysts: Ahmed Madha \u2014 Analyst Tarang Agarwal \u2014 Analyst Nitesh\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/174097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2398"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=174097"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/174097\/revisions"}],"predecessor-version":[{"id":174746,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/174097\/revisions\/174746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=174097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=174097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=174097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}